Kangstem Biotech Co. Ltd Total Liabilities

Latest as of June 2026: ₩11.86 Billion KRW ≈ $8.04 Million USD

Kangstem Biotech Co. Ltd total liabilities. Based on the latest financial reports, Kangstem Biotech Co. Ltd (217730) has total liabilities worth ₩11.86 Billion KRW (≈ $8.04 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Kangstem Biotech Co. Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Kangstem Biotech Co. Ltd (2015–2025)

Total liabilities of Kangstem Biotech Co. Ltd from 2015 to 2025. This chart illustrates how Kangstem Biotech Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 217730 long-term investments to assets to see how much of total assets are deployed in long-term investments.

Kangstem Biotech Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Kangstem Biotech Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Southern Hydropower JSC
VN:SHP
Vietnam ₫64.87 Billion
UVAT Technology Co Ltd
TWO:3580
Taiwan NT$917.63 Million
Norsk Titanium AS
OL:NTI
Norway Nkr14.08 Million
Bellevue Group AG
SW:BBN
Switzerland CHF34.51 Million
STCube Inc
KQ:052020
Korea ₩18.51 Billion
PT Mandiri Herindo Adiperkasa Tbk
JK:MAHA
Indonesia Rp994.58 Billion
Vardhman Holdings Limited
NSE:VHL
India Rs35.50 Million
Excel Industries Limited
NSE:EXCELINDUS
India Rs4.02 Billion

Liability Composition Analysis (2015–2025)

This chart breaks down Kangstem Biotech Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Kangstem Biotech Co. Ltd.

Liquidity & Leverage Metrics

Kangstem Biotech Co. Ltd Total Liabilities Ratios Explained

Kangstem Biotech Co. Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 3.96 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.21 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.17 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Kangstem Biotech Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Kangstem Biotech Co. Ltd (2015–2025)

The table below shows the annual total liabilities of Kangstem Biotech Co. Ltd from 2015 to 2025.

Year Total Liabilities Change
2025-12-31 ₩12.43 Billion
≈ $8.43 Million
-2.90%
2024-12-31 ₩12.80 Billion
≈ $8.68 Million
-65.15%
2023-12-31 ₩36.74 Billion
≈ $24.90 Million
+10.21%
2022-12-31 ₩33.33 Billion
≈ $22.59 Million
-4.97%
2021-12-31 ₩35.07 Billion
≈ $23.77 Million
+13.56%
2020-12-31 ₩30.89 Billion
≈ $20.93 Million
-28.04%
2019-12-31 ₩42.92 Billion
≈ $29.09 Million
+68.30%
2018-12-31 ₩25.50 Billion
≈ $17.28 Million
+13.65%
2017-12-31 ₩22.44 Billion
≈ $15.21 Million
-8.27%
2016-12-31 ₩24.46 Billion
≈ $16.58 Million
+553.16%
2015-12-31 ₩3.75 Billion
≈ $2.54 Million
--

About Kangstem Biotech Co. Ltd

KQ:217730 Korea Biotechnology
Market Cap
$119.13 Million
₩175.79 Billion KRW
Market Cap Rank
#18342 Global
#809 in Korea
Share Price
₩1869.00
Change (1 day)
-2.20%
52-Week Range
₩1397.00 - ₩4615.00
All Time High
₩18836.30
About

Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn's disease. It also provides stem cell conditioned media, such a… Read more